Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 9

Results For "central-nervous-system"

88 News Found

USFDA grants distinct indication for Chronic Sleep Disorder
Drug Approval | August 13, 2021

USFDA grants distinct indication for Chronic Sleep Disorder

Idiopathic hypersomnia is a life-long condition, and the approval of Xywav will be instrumental in providing treatment for symptoms such as excessive sleepiness and difficulty waking, and in effectively managing this debilitating disorder


Lupin receives tentative U.S. FDA approval for Dolutegravir, Lamivudine and TLD tablets
News | July 01, 2021

Lupin receives tentative U.S. FDA approval for Dolutegravir, Lamivudine and TLD tablets

TLD is recommended by WHO, USAID, and PEPFAR as a preferred first-line treatment regimen for the treatment of HIV in adults and pediatric patients weighing at least 35 kg


Sun Pharma’s US Specialty business to grow at 21% CAGR in 2 years
News | June 14, 2021

Sun Pharma’s US Specialty business to grow at 21% CAGR in 2 years

The company expects to see steady performance led by new launches and gradual normalization post the scale-up in vaccination


Lupin donates Oxygen generation plants in Mah, MP & Gujarat
News | June 12, 2021

Lupin donates Oxygen generation plants in Mah, MP & Gujarat

These five oxygen plants with a total capacity of 3,840 cubic meters of oxygen per day have been donated to Madhya Pradesh, Maharashtra, and Gujarat


Lupin receives U.S. FDA approval for HIV-1 drug
Pharma | June 08, 2021

Lupin receives U.S. FDA approval for HIV-1 drug

Emtricitabine and Tenofovir Disoproxil Fumarate tablets had estimated annual sales of US $2.1 billion in the U.S. according to IQVIA MAT March 2021


Lupin launches generic version of Brovana in US
News | June 04, 2021

Lupin launches generic version of Brovana in US

Arformoterol Tartrate Inhalation Solution is for treatment of bronchoconstriction


Lupin receives US $50 mn on achieving cancer milestone
News | May 28, 2021

Lupin receives US $50 mn on achieving cancer milestone

MEK inhibitor compound (LNP3794) developed as part of its oncology pipeline had previously shown pre-clinical activity as a single agent as well as in combination


Nanoform and Celanese explore ways to enhance drug delivery
News | May 25, 2021

Nanoform and Celanese explore ways to enhance drug delivery

Nanoform and Celanese intend to work on formulation development, leveraging each organization's unique formulation expertise.